SOLVEMATE
15.3.2022 09:12:04 CET | Business Wire | Press release
Conversational AI for Customer Service leader Solvemate today announces the addition of multilingual bot management capabilities to its customer service automation platform solution. This platform extension will allow for multiple language chatbot management in a centralized way saving customer service team’s valuable time and effort while maintaining a quality conversational experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005132/en/
Customers Expect Great Local Language Experiences
Companies expanding globally cannot afford to forget the post-sales experience. Common Sense Advisory (CSA) Research study found that 75% of customers prefer to buy from companies which provide post-sales support in their native language. Multilingual support adds quality and value to conversations as misunderstandings are minimized and problems can be solved more efficiently.
Scaling Cost Effectively With Multilingual Self Service
It’s often a costly challenge to grow customer service teams across countries and languages. The new Solvemate multilingual chatbot management allows companies to offer the same great self-service experience with highly personalized chatbots to help customers find the answer they are looking for as they scale globally. Automation offers companies the ability to support languages they may not have in their call center or to help mitigate turnover in languages where they struggle to find local language support in certain parts of the world, especially after hours.
Erik Pfannmöller, co-founder and CEO of Solvemate, comments: “Our customers operate in very competitive markets where the nuances of language can affect a brand’s perception. Managing multiple languages across the customer buying journey is a challenge for any company. This new feature will help companies manage the post-sales experience with AI-driven automation and provide a service advantage to help them grow.”
Improve Bot Maintenance Efficiency
The new feature makes it easy for customer service teams to train and maintain their Solvemate chatbot in multiple languages with a centralized and scalable approach.
The benefits include:
- Extend customer service reach
- Improve global self-service rates
- Reduce the complexity of managing multiple language bots
- Control the quality of translations
Aike Alexander Schnug, Customer Care Manager, FOCUS Bikes, comments: “Multilingual chatbots allow us to grow into new markets in a way that builds trust with customers. Solvemate’s new feature enhancement gives us the flexibility to manage each chatbot individually or implement changes across languages which will save our team time and effort.”
Read more about how to boost your customer’s experience with multi-lingual bots .
Learn more at solvemate.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MANE Selects Kinaxis to Strengthen Global Planning Capabilities29.6.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to provide the digital foundation to strengthen MANE’s global planning capabilities and support its continued planning transformation Kinaxis®(TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that MANE, one of the top five leading organizations worldwide in the flavours and fragrances industry, has selected Kinaxis to modernize its planning capabilities as it accelerates global growth as part of a broader enterprise-wide transformation initiative. Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise and strong commitment to sustainability. The company is investing in more connected, end-to-end planning capabilities to support continued growth and increasing operational complexity worldwide. Following an extensive evaluation process with major competitors in the market, M
From Abu Dhabi to Imola: A2RL Expands Internationally with Historic Autonomous Racing Debut at Iconic Italian Track29.6.2026 12:12:00 CEST | Press release
A2RL’s first international race marks a major step towards its ambition to become the world’s first international championship for fully autonomous racecarsUp to 5 teams including TUM, PoliMOVE, Unimore, Kinetiz and Constructorselected from the 2025 season will compete in the world’s first autonomous multi-car race in EuropeA2RL engaged Italy’s motorsport, engineering and student communities through Motor Valley Fest and a university roadshow ahead of the raceFollowing European debut at Imola, the 2026 season will conclude at Yas Marina Circuit in Abu Dhabi The Abu Dhabi Autonomous Racing League, A2RL, will make its international racing debut on 5 September 2026 in Imola, Italy, bringing up to 5 fully autonomous racecars based on the Dallara Super Formula SF23 to one of the world’s most iconic and demanding racing circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726789/en/ From Abu Dhabi to Imola: A2RL Expands
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom